Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.
暂无分享,去创建一个
M. Weinstein | R. Walensky | R. Parker | N. Rigotti | K. Freedberg | E. Losina | A. Paltiel | T. Baggett | Travis P. Baggett | K. Reddy | R. Parker
[1] Brian A. King,et al. Current Cigarette Smoking Among Adults — United States, 2016 , 2015, MMWR. Morbidity and mortality weekly report.
[2] D. Klein,et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care , 2016, Journal of acquired immune deficiency syndromes.
[3] C. Gibert,et al. Contemplation of Smoking Cessation and Quit Attempts in Human Immunodeficiency Virus–Infected and Uninfected Veterans , 2016, Substance abuse.
[4] A. Siu. Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement. , 2015, Annals of internal medicine.
[5] L. Pacek,et al. Tobacco Use, Use Disorders, and Smoking Cessation Interventions in Persons Living With HIV , 2015, Current HIV/AIDS Reports.
[6] Milton C Weinstein,et al. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. , 2015, JAMA.
[7] B. Nordestgaard,et al. Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] M. Weinstein,et al. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] T. Brennan,et al. Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus , 2015, Annals of Internal Medicine.
[10] J. Skarbinski,et al. Cigarette Smoking Prevalence Among Adults With HIV Compared With the General Adult Population in the United States , 2015, Annals of Internal Medicine.
[11] J. Sterne,et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America , 2015, AIDS.
[12] Brian A. King,et al. Current cigarette smoking among adults - United States, 2005-2014. , 2015, MMWR. Morbidity and mortality weekly report.
[13] Brian A. King,et al. Current Cigarette Smoking Among Adults — United States, 2005–2013 , 2014, MMWR. Morbidity and mortality weekly report.
[14] S. Bojesen,et al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV , 2014, AIDS.
[15] Mardge H. Cohen,et al. Cause-specific mortality among HIV-infected individuals, by CD4+ cell count at HAART initiation, compared with HIV-uninfected individuals , 2014, AIDS.
[16] James J. Goedert,et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.
[17] S. Walmsley,et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.
[18] J. Gatell,et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. , 2013, The Lancet. Infectious diseases.
[19] Clare Brennan,et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.
[20] B. Nordestgaard,et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] Prabhat Jha,et al. 21st-century hazards of smoking and benefits of cessation in the United States. , 2013, The New England journal of medicine.
[22] Michael J Thun,et al. 50-year trends in smoking-related mortality in the United States. , 2013, The New England journal of medicine.
[23] M. Weinstein,et al. Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States , 2013, Annals of Internal Medicine.
[24] Richard D Moore,et al. Establishment, Retention, and Loss to Follow-Up in Outpatient HIV Care , 2012, Journal of acquired immune deficiency syndromes.
[25] A. Mocroft,et al. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. , 2012, International journal of epidemiology.
[26] C. Larsen,et al. Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study , 2012, AIDS.
[27] P. Sax,et al. Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States , 2012, PloS one.
[28] T. Gilmer,et al. Antiretroviral Therapy Adherence, Medication Use, and Health Care Costs During 3 Years of a Community Pharmacy Medication Therapy Management Program for Medi-Cal Beneficiaries with HIV/AIDS , 2011, Journal of managed care pharmacy : JMCP.
[29] A. Justice,et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. , 2011, American journal of respiratory and critical care medicine.
[30] A. Lifson,et al. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. , 2010, American journal of public health.
[31] Richard D Moore,et al. Late presentation for human immunodeficiency virus care in the United States and Canada. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] S. Buskin,et al. Cigarette Smoking and Mortality Among HIV-Infected Individuals in Seattle, Washington (1996–2008) , 2010, AIDS and Behavior.
[33] Richard D Moore,et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] Deepak L. Bhatt,et al. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[35] S. Crystal,et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. , 2009, AIDS education and prevention : official publication of the International Society for AIDS Education.
[36] M. Roberts,et al. Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] J. Ragnaud,et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. , 2007, AIDS patient care and STDs.
[38] J. Benner,et al. Clinical and Economic Outcomes of Nonadherence to Highly Active Antiretroviral Therapy in Patients With Human Immunodeficiency Virus , 2006, Medical care.
[39] Milton C Weinstein,et al. The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.
[40] J. Stockman,et al. Mortality in Relation to Smoking: 50 Years' Observations on Male British Doctors , 2006 .
[41] Milton C Weinstein,et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.
[42] M. Weinstein,et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J. Critchley,et al. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.
[44] S. Self,et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. , 2001, American journal of epidemiology.
[45] M C Weinstein,et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.
[46] D. Coyle,et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.
[47] J. Manson,et al. Smoking Cessation and Time Course of Decreased Risks of Coronary Heart Disease in Middle-Aged Women , 1994 .